Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05745532
EARLY_PHASE1
Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
Sponsor: Shenzhen Hemogen
View on ClinicalTrials.gov
Summary
This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients
Key Details
Gender
All
Age Range
8 Years - 16 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2020-12-01
Completion Date
2025-12-30
Last Updated
2024-11-29
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
β-globin restored autologous hematopoietic stem cells
β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
Locations (1)
Shenzhen Children's Hospital
Shenzhen, Guangdong, China